Synkem's proprietary ligand available for research from Strem Chemicals
US-based Strem Chemicals is now able to supply research quantities of a new proprietary ligand useful for ruthenium-catalysed asymmetric hydrogenation as well as other catalytic processes.
US-based Strem Chemicals is now able to supply research quantities of a new proprietary ligand useful for ruthenium-catalysed asymmetric hydrogenation as well as other catalytic processes.
The new ligand, SYNPHOS, was developed by Professor Genet at the University of Paris and Dr Philippe Dellis's development group at Synkem and has been manufactured at commercial scale.
'Asymmetric hydrogenation with SYNPHOS provides easy and efficient access to chiral molecules,' said Dr Michel Bulliard, Synkem's business development manager. 'When complexed to ruthenium, it is one of the most enantioselective biphenyl atropisomeric ligands for ketone and olefin hydrogenation. We have optimised its steric and electronic properties to produce outstanding results with ruthenium catalysed hydrogenations on substrates such as ketoesters, hydroxyketones, ketophosphonates and succinates.'
The ligand family also has applications in a variety of other catalytic asymmetric processes, including transition metals catalysed asymmetric 1,4-additions, olefin isomerisations, Heck reactions, hydrosilylations and hetero Diels-Alder chemistry.
SYNPHOS is manufactured on an industrial scale starting from readily available raw materials using a classical and straightforward process. 'We have already used this ligand in the manufacture of advanced intermediates that have been further processed into active pharmaceutical ingredients currently in clinical trials,' noted Bulliard.